- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02182128
A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours
A Phase I Open-label Dose-escalation Study of Continuous Twice-daily Oral Treatment With BIBF 1120 in Japanese Patients With Advanced Solid Tumours
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients with a confirmed diagnosis of an advanced, non resectable and/or metastatic solid tumour (except for malignant lymphoma)
- Patients who have not responded to conventional treatment, or for whom no therapy of proven efficacy was available, or who were not amenable to established forms of treatment
Patients recovered from any therapy-related toxicities from previous chemo-, hormone-, immuno-, or radio-therapies (except for epilation) at least over the following periods of time:
- four weeks after chemotherapy (at least 2 weeks after receiving antimetabolite or at least 6 weeks after nitrosourea or mitomycin C)
- two weeks after receiving hormone therapy
- four weeks after receiving radiation therapy (2 weeks after radiation for symptom control)
- two weeks after receiving immunotherapy
- four weeks after surgical procedures
- Age 20 years or older
- Life expectancy of at least 3 months
- Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2
Patients retaining a significant physiological compensatory function and without manifest marked disorders of the hematopoietic system, heart, lung, liver, kidneys, etc., i.e., patients with sufficient baseline organ function
- An absolute neutrophil count more than 1500/mm3
- A platelet count more than 100000/mm3
- A haemoglobin count more than 9.0 g/dL
- Serum creatinine less than 1.5-fold the upper limit value of the normal range
- Bilirubin less than 1.5-fold the upper limit value of the normal range
- Activities of aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) less than 1.5-fold the upper limit value of normal range (if related to liver metastases less than 2.5-fold the upper limit value of the normal range)
- Saturation pulse oxygen (SpO2) level not less than 90%
- No participation in other clinical trials within 4 weeks before start of therapy within this trial
- Written informed consent given that is consistent with ICH-GCP guidelines
Exclusion criteria
- Brain tumour, and/or brain metastases requiring therapy
- History of obvious pulmonary fibrosis or interstitial pneumonitis in chest X-ray including pneumoconiosis or radiation-induced pulmonary fibrosis expanding out of radiation field
- Patients with difficulty in swallowing study medication
- Gastrointestinal disorders that might interfere with the absorption of the study drug (Crohn's disease, ulcerative colitis, broad resection of the stomach)
- Patients with diarrhoea greater than CTCAE grade 2
- Patients within 4 weeks after major surgical procedures or patients with active ulcers or with injuries with incomplete wound healing
- History of autoimmune disease
- History of serious drug hypersensitivity
- History of cardiac infarction or congested heart failure of New York Heart Association Classification (NYHA) II or greater within previous 6 months
- Serious illness or concomitant non-oncological disease difficult to be controled by medication, such as active infectious disease, hepatic failure, renal failure, pulmonary fibrosis, interstitial pneumonitis, hemorrhagic tendency, heart disease (congested heart failure, angina, arrhythmia, etc.), uncontrolled, severe hypertension, and diabetes
- Pregnancy or breastfeeding
- Women and men who are sexually active and unwilling to use a medically acceptable method of contraception until 4 weeks after the last trial visit
- Patients positive in tests of hepatitis B (HBs) antigen, hepatitis C (HCV)antibody, or HIV antibody
- Alcohol or drug abuse
- Patient not suitable for participation in this clinical trial in the opinion of the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BIBF 1120
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of Dose Limiting Toxicities (DLT) associated with increasing doses of BIBF 1120
Time Frame: Up to 36 months
|
Up to 36 months
|
Incidence and intensity of Adverse Events according to Common Toxicity Criteria (CTCAE Version 3.0) associated with increasing doses of BIBF 1120
Time Frame: up to 36 months
|
up to 36 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
maximum tolerated dose (MTD) of BIBF 1120
Time Frame: Up to 36 months
|
Up to 36 months
|
Objective tumour response according to the response evaluation criteria in solid tumours (RECIST)
Time Frame: Up to 36 months
|
Up to 36 months
|
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 12 hours after single dose administration (AUC0-12)
Time Frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours after the first drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours after the first drug administration
|
Change from baseline in peripheral blood biomarkers
Time Frame: Baseline, day 2, day 8, day 30
|
Baseline, day 2, day 8, day 30
|
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 24hours after single dose administration (AUC0-24)
Time Frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable analyte plasma concentration after single dose administration (AUC0-tz)
Time Frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity after single dose administration (AUC0-∞)
Time Frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
The percentage of the AUCtz-∞ that is obtained by extrapolation (%AUCtz-∞)
Time Frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
Maximum measured concentration of the analyte in plasma following a single dose (Cmax)
Time Frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
Time from dosing to the maximum concentration of the analyte in plasma following a single dose (tmax)
Time Frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
Terminal half-life of the analyte in plasma after single dose administration (t1/2)
Time Frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
Terminal rate constant in plasma after single dose administration (λz)
Time Frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
Mean residence time of the analyte in the body after single dose oral administration (MRTpo)
Time Frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
Apparent clearance of the analyte in plasma after single dose extravascular administration (CL/F)
Time Frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
Apparent volume of distribution during the terminal phase λz following extravascular administration (Vz/F)
Time Frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
Area under the concentration-time curve of the analyte in plasma at steady state over the time interval from 0 to 24hours (AUC0-24,ss)
Time Frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmax,ss)
Time Frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
Τime from last dosing to the maximum concentration of the analyte in plasma at steady state over a uniform dosing interval τ (tmax,ss)
Time Frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
Terminal half-life of the analyte in plasma at steady state (t1/2,ss)
Time Frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
Terminal rate constant in plasma at steady state (λz,ss)
Time Frame: Up to 36 month
|
Up to 36 month
|
Minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmin,ss)
Time Frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
Predose concentration of the analyte in plasma at steady state immediately before administration of the next dose (Cpre,ss)
Time Frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
Average concentration of the analyte in plasma at steady state (Cavg)
Time Frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
Mean residence time of the analyte in the body at steady state after oral administration (MRTpo,ss)
Time Frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
Apparent clearance of the analyte in plasma at steady state after extravascular multiple dose administration (CL/F,ss)
Time Frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
Apparent volume of distribution during the terminal phase λz at steady state following extravascular administration (Vz/F,ss)
Time Frame: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
Accumulation ratio (RA)
Time Frame: Up to 36 month
|
Up to 36 month
|
Predose concentration of the analyte in plasma immediately before administration of the n-th dose (Cpre,n)
Time Frame: Day 8, 15 and day 22 after start of treatment
|
Day 8, 15 and day 22 after start of treatment
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1199.19
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedMalignant Tumors | Refractory TumorsFrance
-
AmgenCompletedSolid Tumors | Oncology | Tumors
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
University of California, San FranciscoMerck Sharp & Dohme LLCCompletedCancer | Advanced Solid Tumors | TumorsUnited States
-
Vividion Therapeutics, Inc.RecruitingAdvanced Solid Tumors | Advanced Hematologic TumorsUnited States, Australia
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
Clinical Trials on BIBF 1120
-
Boehringer IngelheimTerminatedCarcinoma, Non-Small-Cell LungJapan
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Squamous Cell Carcinoma | Malignant Uterine Corpus Mixed Epithelial and Mesenchymal NeoplasmUnited States
-
Boehringer IngelheimCompletedCarcinoma, Non-Small-Cell LungJapan
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)CompletedRecurrent Pleural Malignant Mesothelioma | Stage IV Pleural MesotheliomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Boehringer IngelheimCompletedRecurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Stage III Non-small Cell Lung CancerUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Boehringer Ingelheim; National Comprehensive...CompletedRecurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Rectal Adenocarcinoma | Colon Adenocarcinoma | Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal CancerUnited States
-
Boehringer IngelheimCompletedCarcinoma, Non-Small-Cell Lung
-
Boehringer IngelheimCompletedProstatic Neoplasms
-
Boehringer IngelheimCompletedPulmonary FibrosisArgentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czech Republic, France, Germany, Greece, Hungary, Ireland, Italy, Korea, Republic of, Mexico, Netherlands, Portugal, Russian Federation, South Africa, Spain, Taiwan and more